Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Capital Expenditures (2016 - 2025)

Vanda Pharmaceuticals' Capital Expenditures history spans 15 years, with the latest figure at $102000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 52.34% year-over-year to $102000.0; the TTM value through Dec 2025 reached $998000.0, up 103.67%, while the annual FY2025 figure was $998000.0, 103.67% up from the prior year.
  • Capital Expenditures for Q4 2025 was $102000.0 at Vanda Pharmaceuticals, down from $161000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $436000.0 in Q1 2025 and bottomed at -$10000.0 in Q3 2021.
  • The 5-year median for Capital Expenditures is $141000.0 (2021), against an average of $155100.0.
  • The largest annual shift saw Capital Expenditures plummeted 104.07% in 2021 before it skyrocketed 6128.57% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $134000.0 in 2021, then surged by 96.27% to $263000.0 in 2022, then fell by 3.8% to $253000.0 in 2023, then decreased by 15.42% to $214000.0 in 2024, then tumbled by 52.34% to $102000.0 in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Capital Expenditures are $102000.0 (Q4 2025), $161000.0 (Q3 2025), and $299000.0 (Q2 2025).